Xenon Pharmaceuticals Inc
F:XP0
Intrinsic Value
The intrinsic value of one XP0 stock under the Base Case scenario is 6.07 EUR. Compared to the current market price of 27.6 EUR, Xenon Pharmaceuticals Inc is Overvalued by 78%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Xenon Pharmaceuticals Inc
Fundamental Analysis

Revenue & Expenses Breakdown
Xenon Pharmaceuticals Inc
Balance Sheet Decomposition
Xenon Pharmaceuticals Inc
Current Assets | 565.5m |
Cash & Short-Term Investments | 549.6m |
Receivables | 8.6m |
Other Current Assets | 7.3m |
Non-Current Assets | 177.7m |
Long-Term Investments | 141.5m |
PP&E | 17.3m |
Other Non-Current Assets | 18.9m |
Free Cash Flow Analysis
Xenon Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Xenon Pharmaceuticals Inc
Revenue
|
7.5m
USD
|
Operating Expenses
|
-300.5m
USD
|
Operating Income
|
-293m
USD
|
Other Expenses
|
41.5m
USD
|
Net Income
|
-251.4m
USD
|
XP0 Profitability Score
Profitability Due Diligence
Xenon Pharmaceuticals Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
Xenon Pharmaceuticals Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
XP0 Solvency Score
Solvency Due Diligence
Xenon Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Score
Xenon Pharmaceuticals Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
XP0 Price Targets Summary
Xenon Pharmaceuticals Inc
According to Wall Street analysts, the average 1-year price target for XP0 is 49.17 EUR with a low forecast of 37.35 EUR and a high forecast of 60.09 EUR.
Dividends
Current shareholder yield for XENE is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one XP0 stock under the Base Case scenario is 6.07 EUR.
Compared to the current market price of 27.6 EUR, Xenon Pharmaceuticals Inc is Overvalued by 78%.